PubMed日本語 - 脂質異常血症のエゼチミブ治療:最新版。―QLifePro医療翻訳医療翻訳 QLifePro



Ezetimibe therapy for dyslipidemia: an update.

Published date

Ezetimibe therapy for dyslipidemia: an update.


Published date


Curr Pharm Des. 2013; 19; 3107-14;


Niki Katsiki, Eleni Theocharidou, Asterios Karagiannis, Vasilios G Athyros, Dimitri P Mikhailidis


Department of Clinical Biochemistry (Vascular Disease Prevention Clinic), Royal Free Hospital Campus, University College, London Medical School, University College, London (UCL), Pond Street, London NW3, 2QG, United Kingdom.


Ezetimibe, an inhibitor of intestinal cholesterol absorption, can decrease total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglycerides (TGs) and apolipoprotein (apo) B levels and increase high-density lipoprotein cholesterol (HDL-C) levels. Apart from lipid-lowering, ezetimibe may exert certain off-target actions (e.g. anti-inflammatory, anti-atherogenic and antioxidant) thus contributing to a further decrease of cardiovascular disease (CVD) risk.Ezetimibe trials resulted in controversial outcomes with some studies reporting atherosclerosis regression and reductions in CVD events following ezetimibe therapy in combination with a statin while others reported negative results. The results of the ongoing IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) which compares ezetimibe plus simvastatin with simvastatin monotherapy with regard to CVD outcomes after acute coronary syndromes should further elucidate the effect of ezetimibe on CVD events.This review presents the results of up-to-date clinical trials with ezetimibe and summarizes its potential pleiotropic effects. Furthermore, we comment on the administration of ezetimibe in treating high-risk patients [i.e. with diabetes mellitus (DM), metabolic syndrome (MetS), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), peripheral artery disease (PAD) or carotid disease]. The use of ezetimibe either as monotherapy or as add-on therapy in daily clinical practice is also discussed.


結果の進行中のIMProved減少の結果:急性冠症候群がCVD events.Thisレビューに関してエゼチミブの作用を更に説明しなければならなかったあと、CVD結果に関してエゼチミブ+シンバスタチンをシンバスタチン単独療法と比較するVytorin有効性インターナショナル試験(IMPROVEIT)は、エゼチミブで最新の臨床試験の結果を示して、その潜在的多面発現効果を要約する。

460万語の専門辞書を備えた医療者専用翻訳サービス QLifePro医療翻訳